Opens in a new tab or window An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain ...

Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Hereditary angioedema is a rare genetic disease characterized ... were attack-free with no additional treatment during the period from week 1 through week 16. The most common adverse events ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly ...

Intellia Therapeutics fell 20.5% the day after it reported Phase 2 test results for a promising treatment. Explore more ...

Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...

Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status ...